Zhi Tong Cai Jing·2025-10-31 03:39Core Viewpoint - Shanghai Pharmaceuticals (601607) experienced a decline of over 5%, with a current drop of 5.11%, trading at HKD 11.71 and a transaction volume of HKD 109 million [1] Financial Performance - For the first nine months of 2025, the company reported a revenue of CNY 215.07 billion, reflecting a year-on-year growth of 2.60% [1] - The net profit attributable to shareholders for the same period was CNY 5.15 billion, showing a significant increase of 26.96% year-on-year [1] - In the third quarter alone, the company achieved a revenue of CNY 73.48 billion, which is a year-on-year increase of 4.65% [1] - However, the net profit attributable to shareholders in the third quarter was CNY 688 million, representing a year-on-year decline of 38.13%, primarily due to an increase in asset impairment provisions during the quarter [1]